Medicinal and edible composition for preventing and treating osteoporosis and preparation method thereof

Abstract

The invention provides a medicinal and edible composition for preventing and treating osteoporosis and a preparation method thereof. The medicinal and edible composition comprises the following raw materials in parts by weight: 15-24 parts of prepared rehmannia root, 12-15 parts of dogwood, 12-20 parts of Chinese yam, 15-20 parts of astragalus membranaceus, 3-10 parts of angelica sinensis and 10-20 parts of folium cortex eucommiae; the medicinal and edible composition provided by the invention promotes osteoblast differentiation, inhibits osteoclast absorption, regulates bone metabolism balance, increases the maximum load of thighbone, and improves bone density and bone strength by increasing osteoprotegerin and reducing type I collagen C-terminal peptide and tartrate-resistant acid phosphatase. The medicinal and edible composition disclosed by the invention is high in safety, can be developed into medicines, health care products or functional foods, and is applied to prevention and treatment of osteoporosis.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a medicine-food homologous composition for preventing and treating osteoporosis and a preparation method thereof. Background Art

[0002] Osteoporosis is a systemic bone disease caused by a variety of reasons, which leads to decreased bone density and quality, destruction of bone microstructure, increased bone brittleness, and easy fracture. The core pathogenesis of osteoporosis is that various pathogenic factors act on one or more stages of bone formation or reconstruction, resulting in bone absorption greater than bone formation, resulting in decreased bone density.

[0003] Western medicine believes that bone density, or "bone mineral density", is an important indicator of bone quality and reflects the degree of osteoporosis. Bone density can be used as an important basis for predicting the probability of fractures. Clinically, osteoporosis is mostly treated by taking anti-bone resorption drugs to inhibit bone resorption and increase bone density. However, it has the disadvantages of single target, severe drug dependence, large side effects, and high price. For example, long-term use of alendronate sodium may lead to adverse reactions such as atypical femoral fractures and mandibular osteonecrosis.

[0004] In traditional Chinese medicine, osteoporosis is classified into the categories of "bone atrophy", "bone arthritis" and "bone dryness". It is based on kidney essence deficiency and bone marrow reduction, and manifested by blood stasis and obstruction, and loss of bone vascular health. The treatment principle is to mainly tonify the kidney and replenish essence, supplemented by invigorating the spleen and replenishing qi, promoting blood circulation and removing blood stasis, so as to regulate the dynamic balance of bone metabolism and achieve the purpose of preventing and treating osteoporosis.

[0005] By inhibiting bone resorption, promoting bone formation, and regulating the dynamic balance of bone metabolism, bone density may be increased, its maximum load may be increased, and its ability to resist fractures may be enhanced. A large number of studies have shown that Chinese medicine can not only inhibit bone resorption, but also promote bone formation and regulate the dynamic balance of bone metabolism, thereby increasing bone density and enhancing its ability to resist fractures. Chinese patent medicines have achieved certain success in preventing and treating osteoporosis, but the formulation of traditional Chinese medicine compound prescriptions is more dependent on the researcher's own medication experience, and there are problems such as unclear medication rules and time-consuming and labor-intensive drug screening.

[0006] Therefore, people hope to improve bone density, enhance bone strength, and enhance anti-fracture ability through a combination of medicine and food, thereby preventing and treating osteoporosis, and developing a product with significant efficacy, low price, and high safety. Summary of the invention

[0007] In view of the above deficiencies in the prior art, the present invention provides a medicine-food composition for preventing and treating osteoporosis and a preparation method thereof. The medicine-food composition of the present invention can regulate the dynamic balance of bone metabolism, improve bone strength, and enhance its anti-fracture ability, thereby preventing and treating osteoporosis.

[0008] To achieve the above purpose, the specific technical solutions of the present invention are as follows:

[0009] In a first aspect, the present invention provides a medicine-food composition for preventing and treating osteoporosis, the raw materials of which are: 15-24 parts of Rehmannia root, 12-15 parts of Cornus officinalis, 12-20 parts of Dioscorea opposita, 15-20 parts of Astragalus membranaceus, 3-10 parts of Angelica sinensis, and 10-20 parts of Eucommia ulmoides leaves.

[0010] The present invention is based on network pharmacology research, follows the principle of monarch, minister, assistant and envoy, takes Radix Rehmanniae, Fructus Corni and Dioscorea as monarch medicines, and Astragalus and Angelicae Sinensis as ministers, replenishing qi and nourishing blood; assisted by Eucommia ulmoides leaves, nourishing liver and kidney, strengthening tendons and bones; in this way, replenishing qi and nourishing blood, warming yang and tonifying kidney, blood is full of essence, tendons and bones are nourished, so as to achieve the purpose of preventing and treating osteoporosis. Therefore, the present invention uses Chinese medicines including Radix Rehmanniae, Fructus Corni, Dioscorea, Astragalus, Angelicae Sinensis and Eucommia ulmoides leaves as raw materials to prepare a medicine-food homologous composition, and by adjusting the ratio between the raw materials, the prepared medicine-food homologous composition can improve bone density, regulate osteoblast differentiation, inhibit osteoclast absorption, increase the maximum load of bone, and enhance anti-fracture ability, so that it can be applied to the prevention and treatment of osteoporosis, and effectively improve osteoporosis.

[0011] In a second aspect, the present invention provides a method for preparing the edible-medicinal composition for preventing and treating osteoporosis, comprising the following steps: weighing each component according to a proportion, soaking for 1 to 2 hours, decocting for 2 to 3 times, combining the medicinal liquids obtained by multiple decoctions, and concentrating and drying the medicinal liquids to obtain the edible-medicinal composition.

[0012] In a third aspect, the present invention provides use of the medicine-food composition in preparing a product for preventing and treating osteoporosis.

[0013] The edible-medicinal composition increases osteoprotegerin (BGP), decreases C-terminal peptide of type I collagen (CTX-I) and tartrate-resistant acid phosphatase (TRAP), regulates the dynamic balance of bone metabolism, increases bone strength, and enhances its anti-fracture ability, thereby preventing and treating osteoporosis.

[0014] In a fourth aspect, the present invention provides a traditional Chinese medicine preparation for preventing and treating osteoporosis, wherein the traditional Chinese medicine preparation comprises the medicine-food composition.

[0015] Furthermore, the dosage form of the Chinese medicine preparation includes but is not limited to decoction, tablets, powders, powders, pills, granules, oral liquid, and capsules.

[0016] In a fifth aspect, the present invention provides a health product for improving bone density and bone strength, wherein the health product comprises the medicine-food composition.

[0017] Furthermore, the health care products include but are not limited to food, beverages or granules.

[0018] Compared with the prior art, the present invention is beneficial in that:

[0019] The present invention uses an animal model for pharmacodynamic evaluation to reveal the therapeutic effect of the medicine-food homologous composition on osteoporosis. The medicine-food homologous composition of the present invention can improve osteoprotegerin, reduce type I collagen C-terminal peptide and tartrate-resistant acid phosphatase, regulate the dynamic balance of bone metabolism, improve bone strength, and enhance its anti-fracture ability, thereby preventing and treating osteoporosis, and has high safety and is suitable for long-term use. The present invention provides a strong scientific basis for the rational use of drugs in the clinical treatment of osteoporosis, and also lays a foundation for the development of anti-osteoporosis drugs, health products and functional foods. DETAILED DESCRIPTION

[0020] The technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0021] The invention provides a medicine and food homologous composition for preventing and treating osteoporosis. The raw materials are: 15-24 parts of Radix Rehmanniae Preparata, 12-15 parts of Fructus Corni, 12-20 parts of Rhizoma Dioscoreae, 15-20 parts of Radix Astragali, 3-10 parts of Radix Angelicae Sinensis and 10-20 parts of Eucommia Leaf.

[0022] Formula Analysis

[0023] 1. Collection and screening of traditional Chinese medicines for osteoporosis

[0024] Using "kidney deficiency and marrow deficiency", "bone arthritis" and "bone atrophy" as keywords, we searched the "Chinese Medicine Formula Preparation", "National Chinese Patent Medicine Standard Compilation", China National Knowledge Infrastructure Academic Journal Full-text Database, Web of Science, Wanfang Data Knowledge Service Platform and other databases, and obtained a total of 75 prescriptions. Excluded the following prescriptions that did not meet the requirements: single-drug preparations; repeated prescriptions, if the prescription composition was the same but the dosage form was different, only one of them was retained; the efficacy and main indications did not meet the requirements; after sorting, a total of 58 prescriptions were obtained. With reference to the 2020 edition of the "Chinese Pharmacopoeia" (Part I) "Chinese Materia Medica", the names of Chinese medicines in the prescriptions were standardized: ① The processed products were named according to the names of the raw drugs, such as salt Eucommia, cotton Eucommia, Eucommia charcoal, Sichuan Eucommia, and raw Eucommia were standardized as Eucommia, etc.; ② The nicknames and common names of Chinese medicines were standardized as standard names, such as Tudixia was standardized as Tufuling; ③ The raw material extracts were all named according to the raw material name, such as the compound Eucommia fluid extract was standardized as Eucommia; ④ The names of excipients were deleted, such as magnesium stearate.

[0025] 1.1 Medication frequency statistics

[0026] The 58 qualified prescriptions contained a total of 201 Chinese medicines. The frequency of use was recorded as the number of times each Chinese medicine appeared. The total frequency of use was 842 times. The top ten Chinese medicines in terms of frequency were: Rehmannia root, Cuscuta seed, Lycium barbarum, Dioscorea opposita, Eucommia bark, Achyranthes bidentata, Epimedium, Chinese angelica root, Poria cocos, and Cornus officinalis, as shown in Table 1.

[0027] Table 1: Frequency distribution of Chinese patent medicines for osteoporosis

[0028]

[0029] 1.2 Statistics of drug categories

[0030] With reference to the Clinical Chinese Materia Medica, the categories of Chinese medicine were counted. There were 8 categories of the top 40 Chinese medicines in terms of usage frequency. Most of the Chinese medicines used were tonic medicines (frequency 353, accounting for 63.83%); followed by astringent medicines (frequency 44, accounting for 7.96%); and then blood circulation and stasis removal medicines, heat-clearing medicines, and diuretic and dampness-inducing medicines (frequency 40, accounting for 7.32%; frequency 35, accounting for 6.33%; frequency 31, accounting for 5.61%), see Table 2.

[0031] Table 2: Distribution of the top 40 traditional Chinese medicines for osteoporosis by drug category

[0032]

[0033] 1.3 Statistics of the properties and flavors of the medicines and their meridians

[0034] Referring to the 2020 Pharmacopoeia, the classification, nature, flavor and meridians of drugs were counted. In terms of drug nature, warm drugs were the most common (22 types, 314 frequencies, accounting for 57.83%), followed by neutral drugs (8 types, 139 frequencies, accounting for 25.60%). In terms of taste, sweet taste was the most common, accounting for 45.49%, followed by bitter taste, accounting for 16.44%. In terms of meridians, most of them belong to the kidney meridian, accounting for 34.38%, followed by the liver meridian, accounting for 25.46%, and then the spleen meridian, accounting for 13.75%, see Table 3.

[0035] Table 3: Distribution of neutral flavor and meridians of traditional Chinese medicines for osteoporosis

[0036]

[0037] 2. Association rule analysis

[0038] Using language, Apriori algorithm analysis was performed on the traditional Chinese medicine prescription for osteoporosis, and support ≥ 0.2 and confidence ≥ 0.8 were selected for association analysis. Two association rules showed that the support of Chinese yam → Rehmannia glutinosa was 34.48%, the confidence was 0.87, and the lift was 1.441; three association rules showed that the combination of Rehmannia glutinosa + Cornus officinalis + Chinese yam, Rehmannia glutinosa + Poria cocos + Chinese yam, and Lycium barbarum + Rehmannia glutinosa + Chinese yam had high support, confidence, and lift, as shown in Table 4.

[0039] Table 4: Association rule analysis of traditional Chinese medicine for osteoporosis

[0040]

[0041] 3. Formula

[0042] The results of association rule analysis are used as the main medicine, and astragalus and angelica are used as assistants to invigorate qi and nourish blood; eucommia leaves are used as an auxiliary to nourish the liver and kidneys and strengthen tendons and bones; in this way, qi and blood are invigorated, yang is warmed and kidneys are tonified, blood is replenished and essence is abundant, tendons and bones are nourished, so as to achieve the purpose of treating osteoporosis.

[0043] Three candidate prescriptions were obtained, including Combination 1: Rehmannia root - Cornus officinalis - Chinese yam - Astragalus - Angelica sinensis - Eucommia ulmoides leaves; Combination 2: Rehmannia root - Poria - Chinese yam - Astragalus - Angelica sinensis - Eucommia ulmoides leaves; Combination 3: Rehmannia root - Lycium barbarum - Chinese yam - Astragalus - Angelica sinensis - Eucommia ulmoides leaves.

[0044] 4. Network pharmacology prediction analysis

[0045] The target points of ingredients were predicted through databases such as TCMSP and SwissTargetPrediction, and the targets of medicinal materials were obtained after removing duplicates.

[0046] In the GeneCard database and OMIM database, osteoporosis-related disease targets were searched with the keyword "osteoporosis", and 233 targets with strong correlation were obtained. Using the venny2.1.0 platform, the intersection of medicinal material targets and disease targets was taken and visualized for analysis. The results showed that combination 1 obtained 71 potential targets; combination 2 obtained 65 potential targets; combination 3 obtained 66 potential targets; among them, combination 1 had the best target, with a coverage rate of 10.6%, indicating that combination 1 has great potential in the prevention and treatment of osteoporosis, as shown in Table 5.

[0047] Table 5: Prediction analysis of network pharmacology targets of different formulas

[0048]

[0049] Example 1

[0050] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method of which is as follows: prepare rehmannia root, cornus officinalis, yam, astragalus, angelica, and eucommia leaf in a weight ratio of 24:12:12:20:10:20, add 8 times the weight of water as the raw materials and soak for 1 hour, then decoct twice at 100°C, each time for 1 hour, finally combine the two decoctions, concentrate, and freeze-dry to obtain the medicinal and edible composition 1.

[0051] Example 2

[0052] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method of which is as follows: mix Rehmannia root, Cornus officinalis, Chinese yam, Astragalus membranaceus, Angelica sinensis, Eucommia ulmoides, and antler powder in a weight ratio of 18:15:18:15:3:15, add 12 times the weight of water of the raw materials and soak for 2 hours, then boil twice at 100°C, each time for 1 hour, finally combine the two decoctions, concentrate and dry to obtain the medicinal and edible composition 2.

[0053] Example 3

[0054] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method of which is as follows: prepare rehmannia root, cornus officinalis, yam, astragalus, angelica, and eucommia leaf in a weight ratio of 20:13:12:18:8:10, add 12 times the weight of water of the raw materials and soak for 1 hour, then boil for 3 times at 100°C, each time for 1 hour, finally combine the two decoctions, concentrate and dry to obtain the medicinal and edible composition 3.

[0055] Example 4

[0056] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method of which is as follows: mix Rehmannia root, Cornus officinalis, Chinese yam, Astragalus membranaceus, Chinese angelica, and Eucommia ulmoides leaves in a weight ratio of 15:15:20:18:10:15, add 8 times the weight of water as the raw materials and soak for 1 hour, then boil twice at 100°C, each time for 1 hour, finally combine the two decoctions, concentrate and dry to obtain the medicinal and edible composition 4.

[0057] Comparative Example 1

[0058] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method of which is as follows: mix Rehmannia root, Cornus officinalis, Chinese yam, Astragalus membranaceus, and Chinese angelica in a weight ratio of 24:12:12:20:10, add 8 times the weight of water as the raw materials and soak for 1 hour, then boil twice at 100°C, each time for 1 hour, finally combine the two decoctions, concentrate, and freeze-dry to obtain the medicinal and edible composition 5.

[0059] Comparative Example 2

[0060] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method of which is as follows: mix Rehmannia root, Cornus officinalis, Chinese yam, Astragalus membranaceus, and Eucommia ulmoides leaves in a weight ratio of 24:12:12:20:20, add 8 times the weight of water as the raw materials and soak for 1 hour, then boil twice at 100°C, each time for 1 hour, finally combine the two decoctions, concentrate, and freeze-dry to obtain the medicinal and edible composition 6.

[0061] Comparative Example 3

[0062] A medicinal and edible composition for preventing and treating osteoporosis, the preparation method of which is as follows: mix Rehmannia root, Cornus officinalis, Chinese yam, Chinese angelica, and Eucommia ulmoides leaves in a weight ratio of 24:12:12:10:20, add 8 times the weight of water as the raw materials and soak for 1 hour, then boil twice at 100°C, each time for 1 hour, finally combine the two decoctions, concentrate, and freeze-dry to obtain the medicinal and edible composition 7.

[0063] The medicinal and edible compositions prepared in Examples 1-4 and Comparative Examples 1-3 were subjected to pharmacodynamic experiments.

[0064] 1. Experimental animals: 12-week-old SD female rats (purchased from Hubei Provincial Center for Disease Control and Prevention) were selected and the animal experiments were carried out after one week of adaptive feeding.

[0065] 2. Experimental methods

[0066] Modeling and grouping: 77 female SD rats aged 13 weeks were divided into two groups, a sham operation control group of 7 rats (normal group) and an ovariectomy group of 70 rats. They were treated with antibiotics one week after surgery and had free access to water and diet for 12 weeks to complete the model construction.

[0067] 3. Dosage method and grouping: The ovariectomized rats were divided into model group, positive western medicine group, positive traditional Chinese medicine group, experimental group 1, experimental group 2, experimental group 3, experimental group 4, control group 1, control group 2, and control group 3. Each rat was gavaged with 1 mL / 100 g. The specific groups for drug administration are as follows:

[0068] Normal group: gavage with equal dose of pure water;

[0069] Model group: intragastric administration of equal dose of pure water;

[0070] Positive western medicine group: alendronate sodium 6.3 mg / kg;

[0071] Positive Chinese medicine group: Gushukang granules 1.8 g / kg;

[0072] Test group 1: 2.5 g / kg of the edible-medicinal composition prepared in Example 1;

[0073] Test group 2: 2.5 g / kg of the edible-medicinal composition prepared in Example 2;

[0074] Test group 3: 2.5 g / kg of the medicinal and edible composition prepared in Example 3;

[0075] Test group 4: 2.5 g / kg of the edible-medicinal composition prepared in Example 4;

[0076] Control group 1: 2.5 g / kg of the medicine-food composition prepared in Comparative Example 1;

[0077] Control group 2: 2.5 g / kg of the medicine-food composition prepared in Comparative Example 2;

[0078] Control group 3: 2.5 g / kg of the medicine-food composition prepared in Comparative Example 3.

[0079] After the last administration, blood was collected from the abdominal cavity and serum was collected after centrifugation. The right leg was fixed with paraformaldehyde and the left leg femoral tissue was stored in a -80 ℃ refrigerator for subsequent testing of relevant indicators.

[0080] 4. Experimental results

[0081] 4.1 The liver and kidney functions were tested, and the results are shown in Table 6. No obvious abnormalities were found, indicating that the medicine-food composition of the present invention is highly safe.

[0082] Table 6: Changes of liver and kidney function in rats of each group

[0083]

[0084] 4.2 Comparison of bone density among rats in each group

[0085] Bone density measurement helps to assist in the diagnosis of osteoporosis. At present, bone density is the most effective predictor of fracture risk, and the risk of fracture is geometrically related to bone density. In this experiment, the femur of the rat on the right leg of the rat in the test case was scanned using the viva CT80 small animal scanning system (SCANCO Medical AG) to scan the femur of the rat fixed on the stage. The distal end of the femur was scanned along the long axis of the rat femur at a scanning angle of 360° and a scanning resolution of 10 μm. After the scan was completed, the corresponding area was selected on the host, and the imaging analysis software provided by the system was used for 3D reconstruction and analysis and statistics of the relevant data. The results are shown in Table 7. The bone density of rats in the model group decreased significantly, and the bone density of each drug-treated group increased. The effect of test group 1 was equivalent to that of the positive Chinese medicine.

[0086] Table 7: Changes in bone density of rats in each group

[0087]

[0088] Note: Compared with the normal group, #indicates P < 0.05; ## indicates P < 0.01; ### Indicates P < 0.001; compared with the model group, * indicates P < 0.05; ** indicates P < 0.01; *** Denotes P < 0.001.

[0089] 4.3 Changes of bone metabolism markers in serum of rats in each group

[0090] Bone metabolism balance is achieved by the interaction and mutual checks and balances between osteoblasts and osteoclasts, which is of great significance for maintaining the normal function of the skeletal system. The results of the detection of bone metabolism markers in the serum of rats in each group are shown in Table 8. All drug-administered groups can regulate the level of bone metabolism. Among them, the effect of downregulating the expression levels of CTX-Ⅰ and TRAP in the experimental group 1 is more significant, which is equivalent to the positive Chinese medicine group; the positive Western medicine group has the most obvious effect of downregulating the expression levels of CTX-Ⅰ and TRAP, indicating that it has the best inhibitory effect on osteoclast activity; and the experimental group 1 can significantly upregulate the expression level of BGP, indicating that it has a strong ability to promote osteoblast formation.

[0091] Table 8: Changes of bone metabolism markers in rats in each group

[0092]

[0093] Note: Compared with the normal group, # indicates P < 0.05; ## indicates P < 0.01; ### Indicates P < 0.001; compared with the model group, * indicates P < 0.05; ** indicates P < 0.01; *** Denotes P < 0.001.

[0094] 4.4 Comparison of bone biomechanics in rats of each group

[0095] The results of bone biomechanical tests of rats in each group are shown in Table 9. It can be seen from Table 9 that, compared with the normal group, the maximum load of rats in the model group was significantly reduced, and the maximum load of each drug-treated group increased to varying degrees, among which the improvement effect of Test Group 1 was the best, indicating that it has an excellent effect in preventing the risk of fractures.

[0096] Table 9: Changes in the maximum load of femur of rats in each group

[0097]

[0098] Note: Compared with the normal group, # indicates P < 0.05; ## indicates P < 0.01;### Indicates P < 0.001; compared with the model group, * indicates P < 0.05; ** indicates P < 0.01; *** Denotes P < 0.001.

[0099] In summary, the edible and medicinal composition prepared from raw materials including Rehmannia glutinosa, Cornus officinalis, Chinese yam, Astragalus membranaceus, Angelica sinensis and Eucommia ulmoides leaves can improve bone density, regulate osteoblast differentiation, inhibit osteoclast absorption, increase the maximum load of bone, and enhance anti-fracture ability, thereby effectively improving osteoporosis. Moreover, it has high safety and can be used for the prevention and treatment of osteoporosis.

[0100] The above specific embodiments describe the implementation of the present invention in detail, but the present invention is not limited to the specific details in the above embodiments. Within the scope of the claims and technical concept of the present invention, the technical solution of the present invention can be modified and changed in many simple ways, and these simple modifications all belong to the protection scope of the present invention.

Claims

1. A medicine-food composition for preventing and treating osteoporosis, characterized in that: The raw materials are: 15-24 parts of Rehmannia root, 12-15 parts of Cornus officinalis, 12-20 parts of Dioscorea opposita, 15-20 parts of Astragalus membranaceus, 3-10 parts of Angelica sinensis, and 10-20 parts of Eucommia ulmoides leaves.

2. A method for preparing the medicine-food composition according to claim 1, characterized in that: The method comprises the following steps: weighing raw materials, soaking for 1-2 hours, decocting for 2-3 times, combining the medicinal liquids obtained by decocting for multiple times, and concentrating and drying the medicinal liquids to obtain a medicinal and edible composite.

3. Use of the edible-medicine composition according to claim 1 or the edible-medicine composition prepared by the method according to claim 2 in preparing a product for preventing and treating osteoporosis.

4. A Chinese medicine preparation for preventing and treating osteoporosis, characterized in that: The traditional Chinese medicine preparation comprises the medicine-food homologous composition as claimed in claim 1 or the medicine-food homologous composition prepared by the method as claimed in claim 2.

5. The Chinese medicine preparation according to claim 4, characterized in that: The dosage forms of the traditional Chinese medicine preparations include, but are not limited to, decoctions, tablets, powders, powders, pills, granules, oral liquids, and capsules.

6. A health product for improving bone density and bone strength, characterized in that: The health product comprises the medicine-food composition as claimed in claim 1 or the medicine-food composition prepared by the method as claimed in claim 2.

7. The health care product according to claim 6, characterized in that: The health care products include but are not limited to food, beverages or powders.

Images